Document Detail

Dopaminergic drugs in the management of chronic heart failure.
MedLine Citation:
PMID:  1680685     Owner:  NLM     Status:  MEDLINE    
The importance of the dopaminergic system in heart failure is unknown and the therapeutic potential of orally active compounds stimulating dopaminergic receptors has yet to be established. Despite similar acute haemodynamic changes in heart failure and despite a comparable profile of receptor stimulation, oral levodopa (the prodrug of dopamine) and oral ibopamine (the prodrug of epinine) produce opposite effects on plasma norepinephrine and have different pharmacokinetics. Placebo-controlled studies indicate a beneficial effect of ibopamine on exercise tolerance in patients with heart failure, whereas invasive evaluation of left ventricular function indicate that at the doses used in these trials, ibopamine does not act as a positive inotropic drug but rather as a vasodilator. This suggests that DA1 and DA2 receptor stimulation may be beneficial in heart failure. Further studies are, however, needed to specify the exact role of this therapeutic approach in comparison with other agents, such as ACE inhibitors, also able to modulate neuro-humoral activation in heart failure.
H Pouleur; J Raigoso; M F Rousseau
Related Documents :
19996965 - Management of anemia in heart failure.
16250855 - The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotect...
3976695 - Calcium channel blockers in congestive heart failure: theoretic considerations and clin...
9688445 - Digoxin use in patients awaiting heart transplantation for systolic left ventricular fa...
14532945 - Churg-strauss syndrome with myocarditis manifesting as acute myocardial infarction with...
22957665 - Myxomas in all cardiac chambers.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European heart journal     Volume:  12 Suppl C     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1991 Aug 
Date Detail:
Created Date:  1991-11-07     Completed Date:  1991-11-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  29-34     Citation Subset:  IM    
Department of Physiology, University of Louvain, Medical School, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Deoxyepinephrine / analogs & derivatives,  pharmacokinetics,  therapeutic use
Dopamine Agents / pharmacokinetics,  therapeutic use*
Heart Failure / drug therapy*
Hemodynamics / drug effects
Levodopa / therapeutic use
Middle Aged
Myocardial Contraction / drug effects
Pilot Projects
Reg. No./Substance:
0/Dopamine Agents; 0/Levodopa; 501-15-5/Deoxyepinephrine; 66195-31-1/ibopamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors.
Next Document:  Signs of endothelial inflammation in human heart allografts.